Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Syndax Pharmaceuticals Inc's Business Segments
Syndax Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Biopharmaceutical Cancer Therapeutics
Total Revenue
$ 73
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Biopharmaceutical Cancer Therapeutics100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Biopharmaceutical Cancer Therapeutics | $ 73 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Product75.1%
- Collaboration Revenue24.9%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Product | $ 55 | 75.1% |
| Collaboration Revenue | $ 18 | 24.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that specializes in developing novel therapies for a range of cancer indications. The company was founded in 2005 and is headquartered in Waltham, Massachusetts, USA.
Syndax Pharmaceuticals' lead candidate, Entinostat, is a selective histone deacetylase (HDAC) inhibitor that has shown promising results in clinical trials for the treatment of advanced breast cancer, non-small cell lung cancer (NSCLC), and other solid tumors. Entinostat works by inhibiting HDAC activity, which allows for the epigenetic reprogramming of cancer cells and the induction of tumor cell death. Syndax Pharmaceuticals is also developing a pipeline of other potentially groundbreaking therapies for cancer, including SNDX-6352, which is a monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R) and has demonstrated strong anti-tumor activity in preclinical models.
Syndax Pharmaceuticals is committed to developing innovative treatments for cancer patients and has a strong team of scientists, researchers, and executives who are dedicated to making a difference in the lives of patients. The company has received numerous awards and recognitions for its cutting-edge work in the field of oncology, including being named a "Best Place to Work" by the Boston Business Journal and a "Top 10 Breakthrough Technology" by MIT Technology Review.
In addition to its clinical development programs, Syndax Pharmaceuticals is also focused on building strategic partnerships with other companies in the biopharmaceutical industry. The company has established collaborations with several leading academic institutions and pharmaceutical companies, including Merck, Pfizer, and AstraZeneca, to advance the development of its pipeline of therapeutic candidates.
Overall, Syndax Pharmaceuticals is a dynamic and innovative company that is poised to make a significant impact in the field of oncology. With a strong track record of scientific and clinical success, a talented team of professionals, and a commitment to advancing the cause of cancer research and treatment, Syndax Pharmaceuticals is well-positioned to continue making important contributions to the fight against cancer for years to come.
Syndax Pharmaceuticals' lead candidate, Entinostat, is a selective histone deacetylase (HDAC) inhibitor that has shown promising results in clinical trials for the treatment of advanced breast cancer, non-small cell lung cancer (NSCLC), and other solid tumors. Entinostat works by inhibiting HDAC activity, which allows for the epigenetic reprogramming of cancer cells and the induction of tumor cell death. Syndax Pharmaceuticals is also developing a pipeline of other potentially groundbreaking therapies for cancer, including SNDX-6352, which is a monoclonal antibody targeting the colony stimulating factor 1 receptor (CSF1R) and has demonstrated strong anti-tumor activity in preclinical models.
Syndax Pharmaceuticals is committed to developing innovative treatments for cancer patients and has a strong team of scientists, researchers, and executives who are dedicated to making a difference in the lives of patients. The company has received numerous awards and recognitions for its cutting-edge work in the field of oncology, including being named a "Best Place to Work" by the Boston Business Journal and a "Top 10 Breakthrough Technology" by MIT Technology Review.
In addition to its clinical development programs, Syndax Pharmaceuticals is also focused on building strategic partnerships with other companies in the biopharmaceutical industry. The company has established collaborations with several leading academic institutions and pharmaceutical companies, including Merck, Pfizer, and AstraZeneca, to advance the development of its pipeline of therapeutic candidates.
Overall, Syndax Pharmaceuticals is a dynamic and innovative company that is poised to make a significant impact in the field of oncology. With a strong track record of scientific and clinical success, a talented team of professionals, and a commitment to advancing the cause of cancer research and treatment, Syndax Pharmaceuticals is well-positioned to continue making important contributions to the fight against cancer for years to come.
Syndax Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of innovative cancer therapies, with a strong commitment to advancing the treatment landscape for patients suffering from various forms of cancer. The company segments its operations based on the various stages of drug development—clinical, preclinical, and beyond—while also concentrating on specific cancer types that its therapies aim to address.
Clinical Stage Segment
At the forefront of Syndax Pharmaceuticals portfolio is its clinical stage segment, where the company is engaged in the development of novel therapies designed to inhibit cancer cell division and enhance immune response against malignant cells.
1. Entinostat:
- Mechanism: Entinostat is an orally administered, selective class I histone deacetylase (HDAC) inhibitor. Its mechanism of action involves altering gene expression to inhibit cancer cell growth and induce apoptosis (programmed cell death).
- Indications: It is currently being investigated in multiple clinical trials for several cancers, including:
- Breast Cancer: In both HR-positive and triple-negative subtypes, often in combination with other agents.
- Non-Small Cell Lung Cancer (NSCLC): Assessing its efficacy as a monotherapy and in combination therapy settings.
- Melanoma: Exploring its potential to enhance responses to immunotherapy.
2. SNDX-6352:
- Mechanism: This is a monoclonal antibody targeting the colony-stimulating factor 1 receptor (CSF-1R), potentially disrupting the tumor-associated macrophage (TAM) pathway.
- Indications: SNDX-6352 is also in clinical trials for various solid tumors, particularly those where a high presence of TAM can hinder immune responses against the tumor.
Preclinical Stage Segment
Syndax Pharmaceuticals’ preclinical stage focuses on the discovery and early development of compounds that may emerge as groundbreaking cancer treatments. This segment involves thorough research to identify and optimize novel therapeutic targets related to cancer progression and metastasis.
1. IMX-110:
- Mechanism: This drug inhibits the cell cycle protein CDK7, which plays a crucial role in regulating both transcription and cell cycle progression.
- Indications: Currently being explored for application in hematologic malignancies as well as solid tumors, reflecting its versatility in targeting cancer across various types.
Additional Therapeutics and Services
1. Targeted Therapies:
- The products under development are chiefly designed to be targeted therapies. By focusing on specific molecular pathways, these therapies minimize collateral damage to healthy cells, improving patient outcomes and reducing side effects.
2. Delivery Methods:
- Syndaxs drug candidates are typically administered either orally or through injection, ensuring flexibility in treatment regimens and adherence.
3. Clinical Development Services:
- Beyond its proprietary drug development, Syndax also offers a suite of clinical development services to other pharmaceutical and biotech companies focused on oncology. These services include:
- Patient Selection and Enrollment: Assistance in identifying suitable candidates for clinical trials based on stratified patient profiles.
- Clinical Trial Design: Expertise in formulating study frameworks that are scientifically robust and regulatory compliant.
- Data Analysis: Providing analytical support to interpret trial data efficiently, allowing for timely decision-making in the development process.
Commitment to Cancer Treatment
Syndax Pharmaceuticals operates with a clear vision of changing the cancer treatment paradigm. The company is dedicated to fostering innovation through extensive research and development efforts, emphasizing collaborative approaches to cancer therapy that leverage both its internal capabilities and strategic partnerships. By maintaining a robust pipeline of drug candidates and comprehensive clinical service offerings, Syndax seeks to advance the care of cancer patients, ultimately striving for more effective, safer therapeutic options.
The company’s strategic focus positions it to effectively navigate the complexities of oncology drug development and to quickly adapt to the rapidly changing landscape of cancer therapeutics.
Clinical Stage Segment
At the forefront of Syndax Pharmaceuticals portfolio is its clinical stage segment, where the company is engaged in the development of novel therapies designed to inhibit cancer cell division and enhance immune response against malignant cells.
1. Entinostat:
- Mechanism: Entinostat is an orally administered, selective class I histone deacetylase (HDAC) inhibitor. Its mechanism of action involves altering gene expression to inhibit cancer cell growth and induce apoptosis (programmed cell death).
- Indications: It is currently being investigated in multiple clinical trials for several cancers, including:
- Breast Cancer: In both HR-positive and triple-negative subtypes, often in combination with other agents.
- Non-Small Cell Lung Cancer (NSCLC): Assessing its efficacy as a monotherapy and in combination therapy settings.
- Melanoma: Exploring its potential to enhance responses to immunotherapy.
2. SNDX-6352:
- Mechanism: This is a monoclonal antibody targeting the colony-stimulating factor 1 receptor (CSF-1R), potentially disrupting the tumor-associated macrophage (TAM) pathway.
- Indications: SNDX-6352 is also in clinical trials for various solid tumors, particularly those where a high presence of TAM can hinder immune responses against the tumor.
Preclinical Stage Segment
Syndax Pharmaceuticals’ preclinical stage focuses on the discovery and early development of compounds that may emerge as groundbreaking cancer treatments. This segment involves thorough research to identify and optimize novel therapeutic targets related to cancer progression and metastasis.
1. IMX-110:
- Mechanism: This drug inhibits the cell cycle protein CDK7, which plays a crucial role in regulating both transcription and cell cycle progression.
- Indications: Currently being explored for application in hematologic malignancies as well as solid tumors, reflecting its versatility in targeting cancer across various types.
Additional Therapeutics and Services
1. Targeted Therapies:
- The products under development are chiefly designed to be targeted therapies. By focusing on specific molecular pathways, these therapies minimize collateral damage to healthy cells, improving patient outcomes and reducing side effects.
2. Delivery Methods:
- Syndaxs drug candidates are typically administered either orally or through injection, ensuring flexibility in treatment regimens and adherence.
3. Clinical Development Services:
- Beyond its proprietary drug development, Syndax also offers a suite of clinical development services to other pharmaceutical and biotech companies focused on oncology. These services include:
- Patient Selection and Enrollment: Assistance in identifying suitable candidates for clinical trials based on stratified patient profiles.
- Clinical Trial Design: Expertise in formulating study frameworks that are scientifically robust and regulatory compliant.
- Data Analysis: Providing analytical support to interpret trial data efficiently, allowing for timely decision-making in the development process.
Commitment to Cancer Treatment
Syndax Pharmaceuticals operates with a clear vision of changing the cancer treatment paradigm. The company is dedicated to fostering innovation through extensive research and development efforts, emphasizing collaborative approaches to cancer therapy that leverage both its internal capabilities and strategic partnerships. By maintaining a robust pipeline of drug candidates and comprehensive clinical service offerings, Syndax seeks to advance the care of cancer patients, ultimately striving for more effective, safer therapeutic options.
The company’s strategic focus positions it to effectively navigate the complexities of oncology drug development and to quickly adapt to the rapidly changing landscape of cancer therapeutics.